On September 17, 2024, GSK plc announced that Japan's Ministry of Health accepted a drug application for Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma, supported by successful phase III trial results showing improved progression-free survival in patients.